Matches in SemOpenAlex for { <https://semopenalex.org/work/W4206799085> ?p ?o ?g. }
- W4206799085 endingPage "1134" @default.
- W4206799085 startingPage "1126" @default.
- W4206799085 abstract "Purpose The aim of this study was to characterize the patterns of prostate cancer recurrence after brachytherapy (BT) using 2-(3-[1-carboxy-5-([6-18F-fluoropyridine-3-carbonyl]-amino)-pentyl]-ureido)-pentanedioic acid ([18F]DCFPyL) prostate-specific membrane antigen (PSMA) positron emission tomography (PET) and computed tomography (CT) imaging. Methods and Materials Patients were selected from an ongoing prospective institutional trial investigating the use of [18F]DCFPyL PSMA PET and CT in recurrent prostate cancer (NCT 02899312). This report included patients who underwent BT (either monotherapy or boost) and experienced a biochemical failure (BF) defined by the Phoenix definition (prostate-specific antigen [PSA] > 2 ng/mL above nadir). Results Between March 2017 and April 2020, 670 patients underwent [18F]DCFPyL PSMA PET and CT imaging. Of these 670 patients, 93 were treated with BT; 73 underwent monotherapy, and 20 underwent BT boost (19 low-dose rate and 1 high-dose rate). To report on patterns of recurrence outcomes, 86 patients (median prescan PSA 6.0) with a positive [18F]DCFPyL PSMA PET and CT scan and true BF were included. The most common location of relapse was local; 62.8% had a component of local failure (defined as prostate and/or seminal vesicles), and 46.5% had isolated local failure only, with no other sites of involvement. Regional failure occurred in 40.7% of patients, and 36.0% had metastatic failure. Isolated local recurrence was seen in 54.3% of monotherapy patients versus only in 12.5% of boost patients. Metastatic failure was seen in 28.6% of monotherapy patients versus 68.8% of the boost patients. Local recurrences (69.0%) were found within the same prostate biopsy sextant involved with the tumor at diagnosis, and 76.0% of patients with seminal vesicle recurrences had prostate-base involvement at diagnosis. Conclusions Contrary to previous evidence, our study suggests that in prostate BT patients with biochemical recurrence, the most common site of failure is local for the patients treated with monotherapy and metastatic for patients treated with a combination of external beam radiation and BT boost. The aim of this study was to characterize the patterns of prostate cancer recurrence after brachytherapy (BT) using 2-(3-[1-carboxy-5-([6-18F-fluoropyridine-3-carbonyl]-amino)-pentyl]-ureido)-pentanedioic acid ([18F]DCFPyL) prostate-specific membrane antigen (PSMA) positron emission tomography (PET) and computed tomography (CT) imaging. Patients were selected from an ongoing prospective institutional trial investigating the use of [18F]DCFPyL PSMA PET and CT in recurrent prostate cancer (NCT 02899312). This report included patients who underwent BT (either monotherapy or boost) and experienced a biochemical failure (BF) defined by the Phoenix definition (prostate-specific antigen [PSA] > 2 ng/mL above nadir). Between March 2017 and April 2020, 670 patients underwent [18F]DCFPyL PSMA PET and CT imaging. Of these 670 patients, 93 were treated with BT; 73 underwent monotherapy, and 20 underwent BT boost (19 low-dose rate and 1 high-dose rate). To report on patterns of recurrence outcomes, 86 patients (median prescan PSA 6.0) with a positive [18F]DCFPyL PSMA PET and CT scan and true BF were included. The most common location of relapse was local; 62.8% had a component of local failure (defined as prostate and/or seminal vesicles), and 46.5% had isolated local failure only, with no other sites of involvement. Regional failure occurred in 40.7% of patients, and 36.0% had metastatic failure. Isolated local recurrence was seen in 54.3% of monotherapy patients versus only in 12.5% of boost patients. Metastatic failure was seen in 28.6% of monotherapy patients versus 68.8% of the boost patients. Local recurrences (69.0%) were found within the same prostate biopsy sextant involved with the tumor at diagnosis, and 76.0% of patients with seminal vesicle recurrences had prostate-base involvement at diagnosis. Contrary to previous evidence, our study suggests that in prostate BT patients with biochemical recurrence, the most common site of failure is local for the patients treated with monotherapy and metastatic for patients treated with a combination of external beam radiation and BT boost." @default.
- W4206799085 created "2022-01-25" @default.
- W4206799085 creator A5004614891 @default.
- W4206799085 creator A5022511452 @default.
- W4206799085 creator A5036844482 @default.
- W4206799085 creator A5040772609 @default.
- W4206799085 creator A5064944041 @default.
- W4206799085 creator A5076067044 @default.
- W4206799085 creator A5088723836 @default.
- W4206799085 date "2022-04-01" @default.
- W4206799085 modified "2023-10-03" @default.
- W4206799085 title "Patterns of Prostate Cancer Recurrence After Brachytherapy Determined by Prostate-Specific Membrane Antigen–Positron Emission Tomography and Computed Tomography Imaging" @default.
- W4206799085 cites W1571792083 @default.
- W4206799085 cites W1996079495 @default.
- W4206799085 cites W2027294118 @default.
- W4206799085 cites W2055976120 @default.
- W4206799085 cites W2084366964 @default.
- W4206799085 cites W2092588053 @default.
- W4206799085 cites W2136281930 @default.
- W4206799085 cites W2154061463 @default.
- W4206799085 cites W2172902045 @default.
- W4206799085 cites W2281201358 @default.
- W4206799085 cites W2282402220 @default.
- W4206799085 cites W2318502789 @default.
- W4206799085 cites W2337293943 @default.
- W4206799085 cites W2345590823 @default.
- W4206799085 cites W2416718017 @default.
- W4206799085 cites W2518564428 @default.
- W4206799085 cites W2553678345 @default.
- W4206799085 cites W2558756811 @default.
- W4206799085 cites W2569728867 @default.
- W4206799085 cites W2602775013 @default.
- W4206799085 cites W2607240234 @default.
- W4206799085 cites W2610202884 @default.
- W4206799085 cites W2767249739 @default.
- W4206799085 cites W2767882393 @default.
- W4206799085 cites W2767941257 @default.
- W4206799085 cites W2770434684 @default.
- W4206799085 cites W2794131498 @default.
- W4206799085 cites W2884134518 @default.
- W4206799085 cites W2891826471 @default.
- W4206799085 cites W2892177579 @default.
- W4206799085 cites W2895455649 @default.
- W4206799085 cites W2905351080 @default.
- W4206799085 cites W2908600436 @default.
- W4206799085 cites W2910418867 @default.
- W4206799085 cites W2938206213 @default.
- W4206799085 cites W2943710987 @default.
- W4206799085 cites W2950800146 @default.
- W4206799085 cites W2983768183 @default.
- W4206799085 cites W3068427821 @default.
- W4206799085 cites W3096600852 @default.
- W4206799085 cites W3098750885 @default.
- W4206799085 cites W3112578742 @default.
- W4206799085 cites W3125222626 @default.
- W4206799085 cites W3132398728 @default.
- W4206799085 doi "https://doi.org/10.1016/j.ijrobp.2021.12.164" @default.
- W4206799085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34986383" @default.
- W4206799085 hasPublicationYear "2022" @default.
- W4206799085 type Work @default.
- W4206799085 citedByCount "5" @default.
- W4206799085 countsByYear W42067990852022 @default.
- W4206799085 countsByYear W42067990852023 @default.
- W4206799085 crossrefType "journal-article" @default.
- W4206799085 hasAuthorship W4206799085A5004614891 @default.
- W4206799085 hasAuthorship W4206799085A5022511452 @default.
- W4206799085 hasAuthorship W4206799085A5036844482 @default.
- W4206799085 hasAuthorship W4206799085A5040772609 @default.
- W4206799085 hasAuthorship W4206799085A5064944041 @default.
- W4206799085 hasAuthorship W4206799085A5076067044 @default.
- W4206799085 hasAuthorship W4206799085A5088723836 @default.
- W4206799085 hasConcept C121608353 @default.
- W4206799085 hasConcept C126322002 @default.
- W4206799085 hasConcept C126838900 @default.
- W4206799085 hasConcept C126894567 @default.
- W4206799085 hasConcept C201645570 @default.
- W4206799085 hasConcept C20417620 @default.
- W4206799085 hasConcept C2775842073 @default.
- W4206799085 hasConcept C2776235491 @default.
- W4206799085 hasConcept C2777416452 @default.
- W4206799085 hasConcept C2780192828 @default.
- W4206799085 hasConcept C2781406297 @default.
- W4206799085 hasConcept C2989005 @default.
- W4206799085 hasConcept C509974204 @default.
- W4206799085 hasConcept C71924100 @default.
- W4206799085 hasConceptScore W4206799085C121608353 @default.
- W4206799085 hasConceptScore W4206799085C126322002 @default.
- W4206799085 hasConceptScore W4206799085C126838900 @default.
- W4206799085 hasConceptScore W4206799085C126894567 @default.
- W4206799085 hasConceptScore W4206799085C201645570 @default.
- W4206799085 hasConceptScore W4206799085C20417620 @default.
- W4206799085 hasConceptScore W4206799085C2775842073 @default.
- W4206799085 hasConceptScore W4206799085C2776235491 @default.
- W4206799085 hasConceptScore W4206799085C2777416452 @default.
- W4206799085 hasConceptScore W4206799085C2780192828 @default.
- W4206799085 hasConceptScore W4206799085C2781406297 @default.
- W4206799085 hasConceptScore W4206799085C2989005 @default.
- W4206799085 hasConceptScore W4206799085C509974204 @default.